Project Grant R01AI203645
Award Date 9/2/26
Completion Date 8/31/31
Dollars Obligated $719K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27713, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Emory University $1.273 million on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the MISTR+ study, which develops and tests low-touch interventions to improve telehealth HIV preexposure prophylaxis (PrEP) initiation, retention, and re-engagement outcomes among over 100,000 users of telemedicine PrEP services. The project will develop a series of evidence-based, low-cost...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $100,228 on September 30, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct spatial analysis of long-acting injectable pre-exposure prophylaxis (LAI-PrEP) service availability across the United States. The project, titled SAGE PREP (Spatial Availability and Geospatial Exploration of Injectable PrEP Services), integrates clinic location data from an expanded PREP Locator...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $696,200 on May 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the OPAL Study, a pharmacokinetic and pharmacodynamic investigation of emtricitabine/tenofovir disoproxil fumarate (F/TDF) pre-exposure prophylaxis (PrEP) dosing regimens in women across the lifespan. The award funds research to evaluate whether a 2-2-2 event-driven F/TDF dosing regimen...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $814,507 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize HIV-1 reservoir dynamics and immune responses in individuals who acquire HIV-1 while on pre-exposure prophylaxis. The research compares two populations: 20 individuals who acquired HIV-1 while on PrEP (such as long-acting cabotegravir) and 40 individuals who initiated antiretroviral...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $691,288 on July 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the PREP Optimization in Women via Event-Driven Regimens (POWER) study, a pharmacokinetic and pharmacodynamic investigation of emtricitabine/tenofovir disoproxil fumarate (F/TDF) pre-exposure prophylaxis in women receiving exogenous hormone therapy. The study quantifies F/TDF drug...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $100,228 on October 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct natural language processing analysis of social media discussions about pre-exposure prophylaxis (PrEP). The research uses NLP to extract user-generated posts about PrEP from ten years of Google and Reddit data, identifying public inquiries and concerns about initiating or continuing the medication. The...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $853,906 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on same-day pre-exposure prophylaxis (PrEP) initiation in emergency department settings. The research addresses a critical gap in HIV prevention: while PrEP is highly effective, uptake remains low among people at risk, particularly those with limited access to outpatient care....
- The Department of Health and Human Services National Institutes of Health Fogarty International Center awarded $430,734 to Impact Research And Development Organisation on September 13, 2025, under the International Research and Research Training program (CFDA 93.989). The recipient is developing and pilot-testing a multilevel, community-based intervention to reduce pre-exposure prophylaxis (PrEP) stigma and increase PrEP uptake and continuation among adolescent girls and young women ages 15–24...
- The National Institute on Drug Abuse awarded New York University $256,165 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate PREP-RISE, a multi-level photovoice intervention designed to improve pre-exposure prophylaxis (PrEP) uptake and adherence among women who inject drugs. The intervention addresses barriers to PrEP adoption by integrating targeted education during participatory photovoice sessions, building trust, and facilitating warm...
- The National Institute of Allergy and Infectious Diseases awarded Emory University a $2.148 million cooperative agreement on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to design and evaluate an mHealth HIV-prevention intervention delivered to men who have sex with men (MSM) in Peru using WhatsApp. The research, titled "The Eleccion Cohort: Developing and Testing a Scalable, Platform Agnostic Digital Intervention," addresses low uptake of HIV...